Pfavayi, Lorraine T.
Denning, David W.
Baker, Stephen
Sibanda, Elopy N.
Mutapi, Francisca
Funding for this research was provided by:
OAK Foundation
National Institute for Health Research (Global Health Research programme (16/136/33))
Article History
Received: 12 February 2021
Accepted: 8 June 2021
First Online: 24 June 2021
Competing interests
: LTP, FM., SB. and ENS have no competing interests to declare. DWD and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, Bright Angel Therapeutics, Cipla and Metis. He sits on the DSMB for a SARS CoV2 vaccine trial. In the last 3 years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.